KPV

KPV is a short tripeptide (Lys‑Pro‑Val) derived from the C‑terminus of the hormone α‑MSH, which regulates pigmentation and inflammation Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Unlike the full hormone, KPV retains potent anti‑inflammatory activity but is much smaller and simpler α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases. The research focuses on its ability to calm inflammation and help tissues heal, especially in the gut, skin, and mouth PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation+2.

Most studies are preclinical—cell experiments and animal models—so KPV is considered an experimental peptide rather than an approved drug Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. The strongest evidence points to benefits in inflammatory bowel disease (IBD) models, where KPV reduces gut inflammation and supports the intestinal lining PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation+1. Researchers are also exploring KPV for skin irritation, oral mucositis, fatty liver, and even as a targeting tool for vitiligo treatments Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway+3.

KPV works mainly by dampening pro‑inflammatory signals inside cells. Once it enters cells through the PepT1 transporter—a protein that shuttles small peptides into gut and immune cells—it reduces the activity of two key inflammation pathways: NF‑κB and MAPK PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation+1. This leads to lower production of inflammatory cytokines like IL‑8 and TNF‑α, and less tissue damage in models of colitis PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation+1.

KPV also fights oxidative stress, which often triggers inflammation. In liver cells given a fatty acid overload, KPV lowered reactive oxygen species (ROS) and dialed down signaling through ERK, AKT, and mTORC1, resulting in less fat accumulation Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. In skin cells exposed to pollution particles, KPV reduced ROS, apoptosis (programmed cell death), and inflammatory cell death signals Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.

Its origin as a fragment of α‑MSH means KPV taps into the body’s natural melanocortin anti‑inflammatory system without needing the full hormone α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases. This makes it a focused signal for calming immune responses and promoting repair in epithelial tissues—the cells lining the gut, skin, and mouth α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases+1.

The most thoroughly studied effect is improvement in colitis and intestinal inflammation. In mice with chemically induced colitis, oral KPV reduced symptoms, lowered inflammatory markers, and helped heal the intestinal lining PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation+2. Multiple delivery systems—like nanoparticles and hydrogels—enhance this effect by protecting KPV from stomach acid and targeting it to the colon Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis+2.

For the mouth, KPV‑loaded hydrogels eased chemotherapy‑induced oral mucositis, showing less tissue injury and lower inflammation in animal models <i>In situ</i>mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. In skin, KPV protected against damage from fine dust particles, reducing oxidative stress and preventing skin cell death in both cell culture and 3D skin models Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.

Vitiligo research uses KPV as a delivery tag: KPV‑coated liposomes carry gene‑silencing molecules directly to melanocytes, the pigment‑producing cells, and reduced vitiligo development in mice NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development+1. This doesn’t prove KPV alone treats vitiligo, but it shows KPV can help direct drugs to melanocytes.

Early work also suggests possible anti‑steatotic effects in the liver. At high concentrations, KPV decreased fat build‑up in liver cells by cutting ROS and lipogenic signaling Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. In vascular calcification models, combining KPV with rapamycin reduced calcium deposits and inflammation in blood vessels KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy. These areas remain exploratory.

Overall, KPV consistently shows localized anti‑inflammatory and tissue‑protective effects, but the evidence is entirely preclinical Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Research protocols vary by target tissue. For gut inflammation, oral delivery is the primary route because KPV uses the PepT1 transporter for intestinal uptake PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation+1. Standard free peptide may be less effective, so most successful animal studies use advanced oral formulations like nanoparticles or self‑immolative conjugates that boost colonic delivery Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers+1.

• Gut inflammation (colitis models): Oral KPV at formulation‑dependent doses once or twice daily for 1–3 weeks reduced disease severity PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation+2.
• Oral mucositis: A mucoadhesive hydrogel containing KPV applied to mouth lesions reduced inflammation and sped healing in animal models <i>In situ</i>mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis.
• Skin inflammation: Topical KPV applied directly to skin cells or 3D models countered pollutant‑induced stress and apoptosis Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.
• Vitiligo research: KPV‑modified liposomal systems injected near melanocytes in mice helped deliver anti‑inflammatory payloads NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development+1.

Because human data are absent, practitioner protocols (not verified by trials) commonly use oral doses of 250–500 mcg one to two times daily for gut support, or 200–500 mcg daily via subcutaneous injection for systemic anti‑inflammatory goals. These are not evidence‑based but reflect community practice.

Timing often aims for an empty stomach with oral use, to reduce competition for the PepT1 transporter, and topical applications after oral hygiene with no food or drink for 20–30 minutes <i>In situ</i>mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis.

KPV is supplied as a lyophilized powder that must be reconstituted before injection. Bacteriostatic water is the standard diluent for multi‑dose vials, while sterile water is used for single‑use preparations.

Typical concentrations range from 1 mg/mL to 10 mg/mL depending on the volume of diluent added. A common choice is 2 mL of bacteriostatic water into a 10 mg vial, yielding 5 mg/mL, which keeps injection volumes manageable for doses in the 250–1000 mcg range.

After adding diluent, gently swirl (do not shake) until the powder dissolves. The solution should be clear. Reconstituted KPV should be stored in the refrigerator (2–8 °C) and used within 14–30 days when mixed with bacteriostatic water. For longer storage, freeze aliquots at -20 °C, but avoid repeated freeze‑thaw cycles.

For specific dose‑by‑concentration calculations, use the interactive calculator in this section.

KPV’s interactions are largely theoretical because human studies are lacking. Its anti‑inflammatory nature suggests additive effects when combined with other immunosuppressive or anti‑inflammatory drugs, which could increase infection risk.

• Immunosuppressants (e.g., corticosteroids, biologics): Combining with KPV may amplify anti‑inflammatory effects, potentially masking disease activity or lowering immune defenses Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells+2.
• Rapamycin (mTOR inhibitor): KPV itself reduces mTORC1 signaling in liver cells, so adding it to rapamycin could overly suppress this growth pathway Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. A vascular calcification study intentionally paired them, but safety margins are unknown KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.
• Antioxidants (e.g., NAC, curcumin): Since KPV reduces ROS, high‑dose antioxidant supplements might reinforce this action, but the clinical relevance is unclear.
• Peptide stacks: In community protocols, KPV is often stacked with BPC‑157 or GHK‑Cu for healing, but no formal interaction data exist. The main risk is polypharmacy without knowing which agent is responsible for any effect.

Because KPV uses the PepT1 transporter, other peptides or drugs that compete for this transporter could theoretically alter its oral uptake, but this has not been studied PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

KPV is often combined with other research peptides in preclinical and community settings to target different aspects of tissue repair. Common stacks include:

• BPC‑157: Both peptides support gut healing, but through different mechanisms. BPC‑157 promotes angiogenesis and growth factor signaling, while KPV directly dampens inflammation PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Together, they may address both vascular repair and inflammatory control.
• GHK‑Cu: This copper peptide stimulates collagen production and wound remodeling. Stacking with KPV could pair anti‑inflammatory protection with structural regeneration Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.
• TB‑500 (Thymosin Beta‑4 fragment): TB‑500 promotes cell migration and angiogenesis. Adding KPV might add a stronger anti‑inflammatory layer to injury recovery protocols.
• LL‑37: As an antimicrobial peptide, LL‑37 tackles infection while KPV reduces inflammation, creating a complementary antimicrobial‑anti‑inflammatory combination Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.

Evidence for these stacks is almost entirely theoretical or based on individual in‑vitro profiles; controlled combination studies are absent. Community use often pairs KPV with one or two other healing peptides for short‑term gut or injury protocols.

KPV is not approved by the FDA or any other major regulatory agency as a drug Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. It remains an experimental peptide used in laboratory research. No human clinical trials have established its safety or efficacy for any condition.

In the United States, KPV is not scheduled as a controlled substance, but because it lacks FDA approval, it cannot be sold as a dietary supplement or medication. Products marketed for human consumption may be subject to enforcement action by the FDA or FTC.

Internationally, KPV appears in research literature but has no marketing authorization in the EU, UK, Canada, or Australia Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. It is often classified as a research chemical, placing it in a legal gray area for personal use.

In sports, a 2026 review of peptide doping lists KPV among peptides used for anti‑inflammatory and recovery purposes in bodybuilding A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. While WADA has not specifically named KPV, its status as an unapproved substance may make it fall under the S0 category (non‑approved substances). Athletes should treat KPV as prohibited unless a specific ruling states otherwise.

Safety data for KPV in humans is absent; everything known comes from cell and animal experiments Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. In those studies, KPV did not cause obvious toxicity at the doses tested, and it often protected cells from damage Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells+2.

The most likely side effects, based on route, are:

• Oral: mild digestive upset, nausea, or changes in stool frequency (rare in animal models, but theoretically possible).
• Topical: local irritation, burning, or taste changes if used in the mouth.
• Injectable: injection‑site reactions like redness, swelling, or pain.

Theoretical risks include excessive immune suppression if used with other immunosuppressants, masking of infection, and unknown effects on active cancer or fetal development Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Because KPV promotes epithelial repair, there is a theoretical concern—not yet observed—that it might accelerate growth of certain cancers.

No long‑term safety studies exist, and product quality is a major variable. KPV from unregulated sources may be contaminated or mislabeled Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. Anyone using KPV for research should monitor bloodwork (CBC, liver and kidney panels, inflammatory markers) and report any adverse events to a physician.